You have free access to this content

Cancer

Cover image for Cancer

1 September 2003

Volume 98, Issue 5

Pages 885–1104

  1. Commentary

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Informing patients with cancer of ‘new findings’ that may influence their willingness to participate in research studies (pages 885–887)

      Maurie Markman

      Version of Record online: 11 JUL 2003 | DOI: 10.1002/cncr.11607

      Patient informed consent documents routinely state that new information that arises during the course of a study and that may affect patients' willingness to continue their participation will be made available to them. Nonetheless, better-defined criteria are required for deciding when new information must be conveyed to research study participants.

  2. Review Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase (pages 888–893)

      Susan O'Brien, Francis Giles, Moshe Talpaz, Jorge Cortes, Mary Beth Rios, Jianqin Shan, Deborah Thomas, Michael Andreeff, Steven Kornblau, Stefan Faderl, Guillermo Garcia-Manero, Kevin White, Susie Mallard, Emil Freireich and Hagop M. Kantarjian

      Version of Record online: 31 JUL 2003 | DOI: 10.1002/cncr.11620

      • original image

      The sequence of interferon-alpha, cytarabine, and homoharringtonine followed by imatinib (imposed by the discovery of the latter drug) has resulted in an estimated 5-year survival rate of 88%. This suggests that imatinib combination regimens may improve the prognosis in chronic myelogenous leukemia.

  3. Original Articles

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system (pages 894–899)

      Ismail Jatoi, Heiko Becher and Charles R. Leake

      Version of Record online: 28 JUL 2003 | DOI: 10.1002/cncr.11604

      In the U. S., age-adjusted breast carcinoma mortality rates among white and African-American women have been diverging during the last 20 years. Speculation regarding the reasons for this divergence include inequalities in access to healthcare and differences in tumor biology or some extrinsic influences on cancer etiology and behavior. To examine this issue further, the authors compared trends in survival among white and African-American women diagnosed with breast carcinoma in the U. S. Department of Defense (DoD), an equal access healthcare system.

    2. You have free access to this content
      A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (pages 900–907)

      Francisco J. Esteva, Edgardo Rivera, Massimo Cristofanilli, Vicente Valero, Melanie Royce, Anil Duggal, Philippe Colucci, Robert DeJager and Gabriel N. Hortobagyi

      Version of Record online: 25 JUN 2003 | DOI: 10.1002/cncr.11557

      • original image
      • original image
      • original image

      A Phase II study was conducted to evaluate the efficacy, safety, and pharmacokinetics of exatecan mesylate in patients with anthracycline-refractory and taxane-refractory, metastatic breast carcinoma. Exatecan was tolerated well and was moderately effective. Pharmacokinetics were linear.

    3. You have free access to this content
      Histologic grade, stage, and survival in breast carcinoma : Comparison of African American and Caucasian women (pages 908–917)

      Donald Earl Henson, Kenneth C. Chu and Paul H. Levine

      Version of Record online: 1 JUL 2003 | DOI: 10.1002/cncr.11558

      • original image
      • original image
      • original image
      • original image

      According to the Surveillance, Epidemiology, and End Results program, African American women with a diagnosis of breast carcinoma, regardless of age, presented with proportionally more Grade III tumors and fewer Grade I or Grade II tumors for all stages compared with Caucasian women and for all tumor sizes except those smaller than 1.0 cm. For nearly all combinations of stage and grade, the 6-year breast carcinoma–specific survival rate was lower for African American women compared with Caucasian women.

    4. You have free access to this content
      Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older (pages 918–925)

      Gary M. Freedman, Penny R. Anderson, Lori J. Goldstein, Alexandra L. Hanlon, Mary E. Cianfrocca, Michael M. Millenson, Margaret von Mehren, Michael H. Torosian, Marsha C. Boraas, Nicos Nicolaou, Arthur S. Patchefsky and Kathryn Evers

      Version of Record online: 28 JUL 2003 | DOI: 10.1002/cncr.11605

      In the current study, screening mammography was found to be associated with a lesser tumor stage and tumor size and greater eligibility for breast conservation in women with a recent diagnosis of breast carcinoma.

    5. Chest
      You have free access to this content
      Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma (pages 926–931)

      Kiyotaka Yoh, Koichi Goto, Gen-ichiro Ishii, Seiji Niho, Hironobu Ohmatsu, Kaoru Kubota, Ryutaro Kakinuma, Kanji Nagai, Moritaka Suga and Yutaka Nishiwaki

      Version of Record online: 17 JUL 2003 | DOI: 10.1002/cncr.11606

      • original image
      • original image
      • original image

      Thymic carcinoma is a rare neoplasm, and the role of chemotherapy in treating this malignancy is unclear. The current study suggested that a weekly chemotherapy regimen consisting of cisplatin, vincristine, doxorubicin, and etoposide would be an effective treatment for patients with advanced thymic carcinoma.

    6. Gastrointestinal Tract
      You have free access to this content
      Sentinel lymph nodes with technetium-99m colloidal rhenium sulfide in patients with esophageal carcinoma (pages 932–939)

      Hiroyuki Kato, Tatsuya Miyazaki, Masanobu Nakajima, Junko Takita, Makoto Sohda, Yasuyuki Fukai, Norihiro Masuda, Minoru Fukuchi, Ryokuhei Manda, Hitoshi Ojima, Katsuhiko Tsukada, Takayuki Asao, Hiroyuki Kuwano, Noboru Oriuchi and Keigo Endo

      Version of Record online: 27 JUN 2003 | DOI: 10.1002/cncr.11559

      • original image
      • original image
      • original image
      • original image

      Lymphatic mapping with technetium-99m colloidal rhenium sulfide was used to identify the lymphatic basin and was feasible in patients with esophageal squamous cell carcinoma (SCC). Analysis of sentinel lymph nodes using cytokeratin immunohistochemistry increased the staging accuracy of sentinel lymph node. In the future, this technique will be useful for planning the treatment of esophageal SCC.

    7. You have free access to this content
      Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma (pages 940–948)

      Anna H. Wu, Chiu-Chen Tseng and Leslie Bernstein

      Version of Record online: 26 JUN 2003 | DOI: 10.1002/cncr.11568

      Hiatal hernia, in combination with other reflux conditions and symptoms, was associated strongly with the risk of esophageal adenocarcinoma. These associations were more modest for gastric cardia adenocarcinoma. A significant and positive association between body size and history of hiatal hernia/reflux symptoms also was observed.

    8. Genitourinary Disease
      You have free access to this content
      Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy (pages 949–954)

      Michele Albert, Clare M. Tempany, Delray Schultz, Ming-Hui Chen, Robert A. Cormack, Sanjaya Kumar, Mark D. Hurwitz, Clair Beard, Kemal Tuncali, Michael O'Leary, George P. Topulos, Kristin Valentine, Lynn Lopes, Angela Kanan, Daniel Kacher, James Rosato, Hanne Kooy, Ferenc Jolesz, David L. Carr-Locke, Jerome P. Richie and Anthony V. D'Amico

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11595

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Urethral and bladder toxicity after magnetic resonance image-guided brachymonotherapy is rare and may be attributed to the urethral sparing technique of partial prostatic irradiation.

    9. You have free access to this content
      Natural history of surgically treated bladder carcinoma with extravesical tumor extension (pages 955–961)

      Marcus L. Quek, John P. Stein, Peter E. Clark, Siamak Daneshmand, Gus Miranda, Jie Cai, Susan Groshen, Gary Lieskovsky, David I. Quinn, Derek Raghavan and Donald G. Skinner

      Version of Record online: 25 JUN 2003 | DOI: 10.1002/cncr.11569

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Differentiating between microscopic (pT3a) and macroscopic (pT3b) extravesical tumor involvement of transitional cell carcinoma after radical cystectomy does not appear to have prognostic significance. Radical cystectomy provides excellent local control even in locally extensive, extravesical disease.

    10. You have free access to this content
      Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma (pages 962–969)

      Allan Lipton, Ming Zheng and John Seaman

      Version of Record online: 26 JUN 2003 | DOI: 10.1002/cncr.11571

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      A retrospective subset analysis of patients with renal cell carcinoma and bone metastases enrolled in a multicenter, randomized, placebo-controlled study demonstrated that treatment with zoledronic acid (4 mg as a 15-minute infusion) significantly reduced the proportion of patients who developed skeletal complications, delayed the time to the first skeletal complication, and significantly increased the time to progression of bone lesions. Therefore, zoledronic acid provided a significant clinical benefit in patients with bone metastases from renal cell carcinoma, and further investigation of zoledronic acid in this patient population is warranted.

    11. You have free access to this content
      Heat shock proteins HSP27, HSP60, HSP70, and HSP90 : Expression in bladder carcinoma (pages 970–977)

      Thierry Lebret, R. William G. Watson, Vincent Molinié, Amanda O'Neill, Christophe Gabriel, John M. Fitzpatrick and Henry Botto

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11594

      • original image
      • original image

      The 27-kilodalton heat shock protein (HSP27), HSP60, HSP70, and HSP 90 are expressed in normal bladder tissue. Loss of expression of HSP60 and HSP90 is associated with a poor prognosis, i.e., a greater risk of developing an infiltrative recurrence, in patients with bladder carcinoma.

    12. Hematologic Malignancies
      You have free access to this content
      Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease : Unacceptable acute pulmonary toxicity (pages 978–982)

      Jonathan W. Friedberg, Donna Neuberg, Helen Kim, Sarah Miyata, Mary McCauley, David C. Fisher, Tak Takvorian and George P. Canellos

      Version of Record online: 11 JUL 2003 | DOI: 10.1002/cncr.11582

      For the past decade, the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine has been the standard treatment regimen for patients with advanced-stage Hodgkin disease (HD) in the United States. The authors conducted a trial substituting gemcitabine for dacarbazine in the standard regimen for patients with newly diagnosed, high-risk HD. This bleomycin/gemcitabine combination should not be pursued for de novo HD due to unexpected significant pulmonary toxicity.

    13. You have free access to this content
      Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting : Evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 (pages 983–992)

      Alessandra Cuttica, Francesco Zallio, Marco Ladetto, Massimo Di Nicola, Daniele Caracciolo, Michele Magni, Carlo Marinone, Maria Dell'Aquila, Michela Rosace, Alessandro Pileri, Mario Boccadoro, Alessandro M. Gianni and Corrado Tarella

      Version of Record online: 17 JUL 2003 | DOI: 10.1002/cncr.11610

      • original image
      • original image
      • original image
      • original image
      • original image

      The impact of presentation with an age-adjusted International Prognostic Index (aaIPI) score of 2 or 3 was evaluated in 69 consecutive patients (median age, 40 years) with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and peripheral blood progenitor cell autografting. The current study demonstrated the following in patients with aggressive lymphoma: 1) aaIPI score is applicable to patients who are treated with frontline intensive chemotherapy and autografting and 2) the use of frontline intensive chemotherapy in combination with autografting seems to provide benefits for patients with an aaIPI score of 2 but not for patients with an aaIPI score of 3.

    14. You have free access to this content
      Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma (pages 993–1001)

      Uwe Wollina, Reinhard Dummer, Norbert H. Brockmeyer, Helga Konrad, J.-O. Busch, Martin Kaatz, Burkhard Knopf, Hans-Jürgen Koch and Axel Hauschild

      Version of Record online: 24 JUL 2003 | DOI: 10.1002/cncr.11593

      This was a retrospective, multicenter study of pegylated liposomal doxorubicin as a single second-line therapy in 34 patients with cutaneous T-cell lymphoma. A response rate of 88.2% was achieved with good tolerability and limited side effects, suggesting this treatment as a promising alternative to established treatments.

    15. Lung Disease
      You have free access to this content
      Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung (pages 1002–1007)

      Kazuya Uchino, Akihiko Ito, Tomohiko Wakayama, Yu-ichiro Koma, Tomoyo Okada, Chiho Ohbayashi, Shoichi Iseki, Yukihiko Kitamura, Noriaki Tsubota, Yutaka Okita and Morihito Okada

      Version of Record online: 7 JUL 2003 | DOI: 10.1002/cncr.11599

      • original image
      • original image
      • original image
      • original image

      The expression of the tumor suppressor gene TSLC1 was examined in surgical specimens from patients with lung adenocarcinoma. A reduced expression of TSLC1 protein was found to correlate with advanced stage and a worse survival, suggesting that TSLC1 might be an important biomarker of the disease that may serve as a predictor of patient prognosis.

    16. You have free access to this content
      The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma (pages 1008–1013)

      Yuka Fujita, Toshiaki Fujikane, Satoru Fujiuchi, Yutaka Nishigaki, Yasuhiro Yamazaki, Atsushi Nagase, Tetsuo Shimizu, Yoshinobu Ohsaki and Kenjiro Kikuchi

      Version of Record online: 17 JUL 2003 | DOI: 10.1002/cncr.11611

      • original image
      • original image
      • original image

      The authors evaluated whether the in situ detection of human telomerase reverse transcriptase (hTERT) had prognostic and diagnostic relevance in patients with nonsmall cell lung carcinoma (NSCLC) and found that mRNA expression may be useful for the diagnosis of NSCLC and may be an independent prognostic factor for patients with NSCLC.

    17. Neuro-Oncology
      You have free access to this content
      Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors (pages 1014–1020)

      Jaimie Bakish, Darren Hargrave, Nauman Tariq, Normand Laperriere, James T. Rutka and Eric Bouffet

      Version of Record online: 1 JUL 2003 | DOI: 10.1002/cncr.11598

      • original image
      • original image
      • original image

      Multimodality treatment of medulloblastoma/primitive neuroectodermal tumors (PNET) results in significant nutritional morbidity, primarily as a result of intensive chemotherapy regimens. Dietetic input for pediatric patients with medulloblastoma/PNET is essential, and the implementation of enteral feeding in these children can help to reverse their nutritional morbidity.

    18. You have free access to this content
      Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy (pages 1021–1028)

      Bouthaina S. Dabaja, Peter McLaughlin, Chul S. Ha, Barbara Pro, Christina A. Meyers, Lee F. Seabrooke, Richard B. Wilder, Athanassios P. Kyritsis, H. Alejandro Preti, W. K. Alfred Yung, Victor Levin, Fernando Cabanillas and James D. Cox

      Version of Record online: 17 JUL 2003 | DOI: 10.1002/cncr.11627

      • original image

      Hyperfractionated whole brain radiation therapy with concurrent bromodeoxyuridine and chemotherapy for the treatment of primary central nervous system lymphoma is reported to result in modest disease control but is associated with unacceptable toxicity.

    19. Sarcoma
      You have free access to this content
      Differential gene expression in leiomyosarcoma (pages 1029–1038)

      Keith M. Skubitz and Amy P. N. Skubitz

      Version of Record online: 31 JUL 2003 | DOI: 10.1002/cncr.11586

      • original image
      • original image
      • original image
      • original image
      • original image

      Using microarray analysis, differences in gene expression between leiomyosarcomas and leiomyomas, normal myometrium, and other tissues were detected. These changes in gene expression may yield clues regarding the pathophysiology of leiomyosarcomas.

    20. Discipline

      Medical Oncology
      You have free access to this content
      Treatment of febrile neutropenic patients with cancer who require hospitalization : A prospective randomized study comparing imipenem and cefepime (pages 1039–1047)

      Issam I. Raad, Carmen Escalante, Ray Y. Hachem, Hend A. Hanna, Rola Husni, Claude Afif, Maha R. Boktour, Estella E. Whimbey, Dimitrios Kontoyiannis, Kalen Jacobson, Hagop Kantarjian, L. Martin Levett and Kenneth V. I. Rolston

      Version of Record online: 17 JUL 2003 | DOI: 10.1002/cncr.11613

      • original image

      The authors compared the efficacy and safety of imipenem and cefepime in the treatment of adult patients with cancer who had fever and neutropenia requiring hospitalization according to Infectious Disease Society of America (IDSA) criteria. The results demonstrated that the use of either imipenem or cefepime in accordance with IDSA guidelines in the treatment of moderate to high-risk hospitalized patients with febrile neutropenia was associated with high and comparable efficacy.

    21. You have free access to this content
      Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer : Report of an International Compassionate Use Study (pages 1048–1054)

      André Bosly, Anne Sonet, C. Ross Pinkerton, Geoffrey McCowage, Dominique Bron, Miguel A. Sanz and Hendrik Van den Berg

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11612

      • original image
      • original image

      In an international compassionate use study, 166 children and 112 adults with cancer received rasburicase for the management of plasma uric acid levels during chemotherapy. A dramatic reduction in uric acid levels was observed in almost all patients and was associated with few drug-related side effects, thus confirming the safety and efficacy of rasburicase.

    22. Pathology
      You have free access to this content
      Breast carcinoma in pregnant women : Assessment of clinicopathologic and immunohistochemical features (pages 1055–1060)

      Lavinia P. Middleton, Mitual Amin, Karin Gwyn, Richard Theriault and Aysegul Sahin

      Version of Record online: 31 JUL 2003 | DOI: 10.1002/cncr.11614

      • original image
      • original image

      Breast carcinoma is the most common carcinoma occurring in pregnant women. Breast carcinoma in pregnant women share many histologic and prognostic similarities with breast carcinoma occurring in other young women.

    23. Psychological Oncology
      You have free access to this content
      Psychological well being and quality of life in ovarian cancer survivors (pages 1061–1071)

      Betty Ferrell, Stephany L. Smith, Carey A. Cullinane and Cindy Melancon

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11291

      • original image

      A unique analysis is presented of psychological well being across the disease trajectory and survival/coping techniques based on 21,806 letters that were written by women with ovarian cancer.

    24. Radiation Oncology
      You have free access to this content
      Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy (pages 1072–1079)

      Daniel Shasha, Martine J. George and Louis B. Harrison

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11616

      • original image
      • original image

      Once-weekly dosing with epoetin-α is reported to increase hemoglobin levels, decrease transfusion requirements, and improve the functional status and quality of life in anemic patients with nonmyeloid malignancies who are receiving radiation therapy concomitantly or sequentially with chemotherapy. The clinical benefits and safety profile of once-weekly epoetin-α in this setting appear similar to those observed in anemic cancer patients receiving chemotherapy, and similar to those reported with a dosing schedule of three times weekly.

    25. Translational Research
      You have free access to this content
      Expression of translation initiation factor eIF-2α is increased in benign and malignant melanocytic and colonic epithelial neoplasms (pages 1080–1088)

      Igor B. Rosenwald, Songtao Wang, Lou Savas, Bruce Woda and James Pullman

      Version of Record online: 22 JUL 2003 | DOI: 10.1002/cncr.11619

      • original image
      • original image
      • original image
      • original image

      The authors used immunohistochemistry to establish the expression of translation initiation factors eIF-2α and eIF-4E as well as cyclin D1 in melanocytic nevi and melanomas and the expression of eIF-2α in colonic adenomas and carcinomas. The findings suggest that increased expression of eIF-2α takes place in both benign and malignant neoplasms of melanocytes and colonic epithelium.

    26. You have free access to this content
      CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies : Possible involvement of regulatory T cells in disease progression (pages 1089–1099)

      Tetsuro Sasada, Motohide Kimura, Yuka Yoshida, Michiyuki Kanai and Arimichi Takabayashi

      Version of Record online: 16 JUL 2003 | DOI: 10.1002/cncr.11618

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      CD4+CD25+ regulatory T cells, which may be closely related to immunosuppression and tumor progression, were more prevalent (relative to CD4+CD25 T cells) in peripheral blood and ascites in patients with gastrointestinal malignancies compared with healthy individuals. This finding suggests that the use of immunomodulatory therapy to treat patients with gastrointestinal malignancies may be an effective strategy.

  4. Book Review

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. You have free access to this content
  5. Correspondence

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Serum endostatin predicts tumor vascularity in hepatocellular carcinoma (page 1101)

      Mesut Tez and Selda Tez

      Version of Record online: 27 JUN 2003 | DOI: 10.1002/cncr.11589

    2. You have free access to this content
      Author reply (pages 1101–1102)

      Dipok Kumar Dhar, Takashi Ono, Akira Yamanoi and Naofumi Nagasue

      Version of Record online: 27 JUN 2003 | DOI: 10.1002/cncr.11590

    3. You have free access to this content
    4. You have free access to this content
      Author reply (page 1103)

      Deborah Dillon, Darryl Carter and Bruce Haffty

      Version of Record online: 26 JUN 2003 | DOI: 10.1002/cncr.11597

  6. Erratum

    1. Top of page
    2. Commentary
    3. Review Articles
    4. Original Articles
    5. Book Review
    6. Correspondence
    7. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION